Dermatology · Clinical trials
Alopecia Areata Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About alopecia areata — and why its trials are hard
Alopecia areata is a chronic, T-cell-mediated autoimmune disease in which the immune system attacks anagen hair follicles, producing patchy, sometimes total (alopecia totalis) or universal (alopecia universalis) nonscarring hair loss. It affects roughly 2% of people over a lifetime, often with substantial psychosocial burden. Disease activity is quantified by the Severity of Alopecia Tool (SALT), which scores percentage scalp hair loss from 0 to 100. Interferon-gamma and JAK-STAT signaling drive the collapse of follicular immune privilege, making Janus kinase inhibition the central therapeutic advance. Historic options (intralesional and systemic corticosteroids, topical immunotherapy, minoxidil) lacked strong controlled evidence for extensive disease. Since 2022, three oral JAK inhibitors have gained FDA approval for severe disease, the first-ever systemic approvals, transforming the treatment landscape and defining SALT score 20 or less as the accepted regulatory efficacy benchmark for meaningful scalp coverage.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Baricitinib (Olumiant) | 2022 | Severe alopecia areata in adults (first systemic approval) | BRAVE-AA1 and BRAVE-AA2 (Phase 3, NEJM 2022) | SALT score ≤20 at week 36 | Approximately 35-39% of patients on baricitinib 4 mg achieved SALT ≤20 versus about 3-5% on placebo |
| Ritlecitinib (Litfulo) | 2023 | Severe alopecia areata in patients aged 12 and older | ALLEGRO-2b/3 (Phase 2b/3, Lancet 2023) | SALT score ≤20 at week 24 | About 23% on ritlecitinib 50 mg achieved SALT ≤20 versus roughly 1-2% on placebo |
| Deuruxolitinib (Leqselvi) | 2024 | Severe alopecia areata in adults | THRIVE-AA1 and THRIVE-AA2 (Phase 3) | SALT score ≤20 at week 24 | Approximately 30-42% on deuruxolitinib 8 mg twice daily achieved SALT ≤20 versus under 1% on placebo |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in alopecia areata development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Apremilast — Phase 2 randomized placebo-controlled study in moderate-to-severe alopecia areata | Did not show meaningful hair regrowth benefit; PDE4 inhibition failed to demonstrate efficacy and the program was not advanced | Alopecia areata is driven predominantly by JAK-STAT/interferon-gamma signaling rather than PDE4-mediated inflammation, so the mechanism was poorly matched to disease biology |
Choosing the right endpoint
Primary endpoints that matter in alopecia areata trials
- SALT score ≤20 — Primary regulatory endpoint for the JAK inhibitors; represents 80% or more scalp coverage, considered clinically meaningful
- SALT score ≤10 — More stringent secondary threshold indicating near-complete scalp regrowth
- Eyebrow and eyelash assessment — Clinician-reported outcomes capturing regrowth at cosmetically important non-scalp sites
- Patient Global Impression of Change — Patient-reported measure of overall improvement and treatment satisfaction
How iNGENū runs alopecia areata trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Frequently asked questions
Alopecia Areata clinical trials — FAQs
What does SALT score 20 or less mean?
Which drug was the first systemic therapy approved?
Do JAK inhibitors cure alopecia areata?
Ready to discuss your alopecia areata trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal